Index Ventures closes life sciences fund at €150m

Investors
Investors in the fund include previous LPs and pharmaceutical companies GlaxoSmithKline and Johnson & Johnson. The latter will join a scientific advisory board to provide advice on prospective investments.

Investments
The fund intends make investments in companies with one or two projects with first-in-class or best-in-class mechanisms of action and targets of unmet medical need. It will primarily operate within Europe, but considers American opportunities as well.

People
Partner Francesco de Rubertis worked on fundraising for Index Ventures.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• UK / Ireland
• Now researching
• Healthcare
• United Kingdom
• Index Ventures